Longevity drug more than doubles endurance in mice
A compound that regulates cellular energy balance more than doubled running endurance in mice without taking any muscle mass. Cambrian Bio has already shared results from its first small human trials.
Biotech company Cambrian Bio has developed a compound that activates a protein that monitors the energy status of cells. This protein plays a role in processes linked to nutrition and aging that researchers have studied for decades. When cells detect lower energy availability, the protein triggers a set of processes that help cells survive and function more efficiently.
Results in mice
According to James Peyer, co-founder and chief executive of Cambrian Bio, mice on the drug lost weight without losing lean mass (muscle), and performed more than twice as well on endurance tests. These are striking results, but they were achieved in animals. Whether the same effects occur in people is not yet known.
First human studies
Cambrian Bio has also completed small initial studies in humans, and Peyer shared results in the interview, though full details on the size and outcomes of those studies are not provided in the source. The company focuses on what Peyer calls ‘gerotherapeutics’: drugs that do not treat one disease but slow the biological aging process itself, so that multiple age-related diseases appear later or less severely.
Want to research this yourself?
Search for example:
- AMPK activator aging nutrient-sensing pathways | gerotherapeutics preventive medicine aging | endurance muscle preservation longevity